Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00377572 · ClinicalTrials.gov registry record · Phase 4
Inner-City Anti-IgE Therapy for Asthma
A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 4
- Development phase
- 419
- Enrollment target
NCT00377572 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 419 participants.
The verdict
NCT00377572, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 419 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if adding omalizumab to standard asthma treatment results in a safer, more effective, and longer lasting asthma treatment strategy than standard treatment alone, in inner-city children with mild to severe asthma.
Interventions
- BIOLOGICAL omalizumab
- BIOLOGICAL omalizumab placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00377572
The ClinicalTrials.gov registry entry for NCT00377572 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which omalizumab is the first listed.
NCT00377572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00377572 about?
NCT00377572 is a clinical study titled "Inner-City Anti-IgE Therapy for Asthma". The purpose of this study is to find out if adding omalizumab to standard asthma treatment results in a safer, more effective, and longer lasting asthma treatment strategy than standard treatment alone, in inner-city children with mild to severe asthma.
What is the current status of trial NCT00377572?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 419 participants. The study started on 2006-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00377572?
The interventions under investigation include: omalizumab (BIOLOGICAL), omalizumab placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00377572?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.